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ABSTRACT 
Chemokines, largest family of cytokines, regulate cell trafficking through interaction of GPCR. 
Chemokines are classified into categories depending on the pattern of  cysteine residue. 
Chemokine receptor type 4 (CXCR4) is a cell surface receptor important when cells migrate during 
inflammation and has been linked to various disease pathways such as cancer metastasis, 
inflammation disease, HIV-1 proliferation, and auto-immune disorders. CXCR4 along with its 
cognate ligand CXCL12 have been projected to regulate metastases sites in invasion of breast 
cancer cells. Several pyridine analogues have been synthesized as potential CXCR4 antagonists 
via reductive amination. These compounds are analyzed through proton and carbon NMR, high-
resolution mass spectrometry, and melting point. After synthesis, the analogues undergo several 
assays at Emory University in Shim lab. The assays include Binding affinity assay, Matrigel 
invasion assay, and Carrageenan paw edema test. 
 
INDEX WORDS: Small molecules, CXCR4, CXCL12, Inhibitors, Cancer metastasis, 
Inflammation, Reductive amination, Binding affinity assay, Matrigel invasion assay, Carrageenan 
paw edema test.   
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1 INTRODUCTION 
1.1 Chemokines 
Cytokines are small proteins involved in cell signaling and immune response. Chemokines are the 
largest family of cytokines and are classified as chemotactic cytokines for various types of 
leukocytes.1 They regulate cell trafficking through interaction with seven transmembrane G-
protein coupled receptors (GPCRs). GPCRs are a large family of proteins that help activate signal 
transduction inside the cell by detection of molecules outside the cell. There are 50 chemokines 
and 20 chemokine receptors in the human chemokine system.2  
Chemokines can be classified into four different categories (CXC, CC, C, and CX3C) depending 
on the pattern of the cysteine residue on the N-terminus.3 Chemokines can be promiscuous,4 
shared,4 specific,5 or viral.6 Promiscuous chemokines bind to various receptors and the receptors 
bind to various ligands.7 An example of a promiscuous chemokine is CXCL12, which binds to 
both CXCR4 and CXCR7.8 Shared chemokines bind to one family, whereas a specific chemokine 
receptors only bind to one specific partner. Viral chemokines are the ones that live in viral 
organisms. This work focuses on the interaction between the chemokine CXCL12 with the 
chemokine receptor CXCR4. 
 
1.2 CXCR4 
CXC chemokine receptor type 4 (CXCR4) is a type of seven transmembrane GPCR (Figure 1 and 
3).9 It had been previously known by few other names: CD184, LESTR,10 and fusin.11 CXCR4 has 
been linked to various disease pathways such as autoimmune diseases, inflammatory diseases, 
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HIV-1 proliferation, and cancer metastasis.12 It was discovered as a co-receptor in human 
immunodeficiency virus (HIV) entry. The receptor is expressed in various tissues such as stomach, 
spleen, and brain.  
 
Figure 1:Pathways regulated by CXCR4. 
Image taken without permission from: Choi, Won-Tak; Duggineni, Srinivas; Xu, Yan; Huang, 
Ziwei; An, Jing. Drug Discovery Research Targeting the CXC Chemokine Receptor 4 
(CXCR4). J. Med. Chem. 2012. 55. 977-994. 
 
 
1.2.1 CXCR4 and CXCL12 
CXCR4 only interacts with its chemokine ligand 12 (CXCL12) to trigger downstream 
physiological responses in the body. CXCL12 is also called stromal-derived-factor-1 (SDF-1).13 
SDF-1 has found to also interact with CXCR7. CXCR4/SDF-1 interaction plays an important role 
in signaling pathways for pathological responses such as gene transcription, chemotaxis, and cell 
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survival and proliferation.12 They can also facilitate metastasis and tumor growth by recruiting 
distal stroma.14 Disruption of CXCR4/CXCL12 causes pathways to delay or block metastasis, 
mobilization of immune cells and inflammatory cells, cell survival, intracellular calcium 
modulation, gene transcription, and cell adhesion.15  
 
1.2.2 Structure of CXCR4 and CXCL12 
Crystal structure of CXCR4 molecule with the protein bound to small molecule antagonist, IT1t, 
(Figure 2) attached to it was first reported by Ryu et al. in 2007.16 The crystal structure was 
incomplete because some amino acids were missing from the N-terminus.17 An NMR structure of 
CXCR4’s N-terminus in complex with CXCL12 was reported by Veldkamp et al. in 2008.18 This 
NMR helped fill in the gaps for the structure and help identify the interaction between CXCR4 
and CXCL12. Although, a crystal structure of CXCR4 and CXCL12 bound together is not 
available. 
 
Figure 2: Structure of Small molecule antagonist, IT1t. 
 
The main fold of CXCR4 contains 7 α-helices (Figure 3).19 These helices are linked with three 
extracellular loops (ELC), three intracellular loops (ICL) and two disulfide bonds. ECL1 links 
helices II and III, ELC2 links helices IV and V, and ECL3 links helices VI and VII. ICL1 links 
helices I and II, ICL2 links helices III and IV, and ICL3 links V and VI and the C-terminus. A 
N
H
N
S
N
SNH3C
H3C
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disulfide bond links Cys247 on helix VII to Cys28 in the N-terminus and another disulfide bond 
links Cys109 with Cys186 on ECL2, which shapes the binding pocket for the ligand.17  
The structure of CXCL12 is characterized by a N-terminus, a three stranded b-sheet packed against 
an α-helix, and a RFFESH motif (Figure 3).19 Studies on binding and signaling of CXCR4 suggest 
a “two-site” model. “Site-one” docking domain consists of the chemokine core domain responsible 
for the docking of chemokine to its receptor.  The most important core domain for binding of 
CXCR4 in CXCL12 is RFFESH motif. “Site-two” signaling trigger consists of the chemokine N-
terminus which is responsible for activation of CXCR4 signal.17  
 
 
Figure 3: Structure of CXCR4 and CXCL12.  
Image taken without permission from Pawig, L.; Klasen, C.; Weber, C.; Bernhagen, J.; Noels, 
H., Diversity and Inter-Connections in the CXCR4 Chemokine Receptor/Ligand Family: 
Molecular Perspectives. Frontiers in Immunology 2015, 6 (429). 
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1.2.3 Binding of CXCR4 and CXCL12 
Studies have shown that neutralizing CXCR4/CXCL12 interaction significantly impairs cell 
migration and the metastasis of breast cancer cells.20 NMR studies of CXCL12 showed the 
interaction of CXCR4 and CXCL12 to be a two-site binding model.18 The first site is where the 
CXCL12 RFFESH loop interacts with the N-terminal of CXCR4 and the second site is where the 
N-terminal of CXCL12 interacted with the helices of CXCR4.21  
The interactions between CXCR4 and CXCL12 is vital for other physiological processes such as 
hemostasis and trafficking of immune cells. Therefore, completely blocking the active site with an 
antagonist may have unwanted physiological side effects. Small molecule antagonists would not 
block the interaction of CXCR4 and CXCL12 in the first binding step but would block the 
interaction of the N-terminal of CXCL12 with the helices.22 To this end, our approach in this work 
is to design and synthesize small molecules that can modulate the effects of the CXCR4/CXCL12 
axis on cancer metastasis and inflammation. 
 
1.2.4 CXCR4 Antagonist 
The interaction between CXCR4 and CXCL12 plays an important role in disease related pathways. 
Blocking this interaction has become a leading strategy in an attempt to alleviate these pathways 
or even selectively accelerate normal physiological pathways. Several small molecules have 
succeeded in blocking this interaction and have been shown to mitigate cancer metastasis and have 
anti-inflammatory activity. 
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One group of small molecules that have potential as CXCR4 antagonists have a common central 
benzene ring. These compounds are classified as p-xylyl-enediamines (Figure 4).23 Other 
categories of CXCR4 antagonists are: cyclic pentapeptide-based, quinone-based, indole-based, 
tetrahydroquinoline-based and pyrimidine-based antagonist (Figure 4).24-25 Our work focuses on 
the modification of p-xylyl-enediamines. 
 
Figure 4: Examples of p-xylyl-enediamine-based, cyclic-based, quinolone-based, indole-
based, tetrahydroquinoline-based, and pyrimidine-based CXCR4 antagonists.2 
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1.3 Diseases and CXCR4 
1.3.1 Cancer Metastasis 
Cancer is a disease that can grow in any part of the body and spread to a different part of the body. 
The disease stems from a mutation in DNA in a cell. Normal human cells grow and divide to form 
new cells. As the cells grow old or damaged, new cells take their place and they die. When a 
mutation in a cell takes place, the cell becomes abnormal.26 Cancerous cells tend to grow and 
divide and not undergo the cell death.26 
CXCR4 is over expressed in various human cancers including kidney, lung, brain, prostrate, breast, 
pancreas, ovarian, and melanomas. It contributes to metastasis, tumor growth, angiogenesis, and 
therapeutic resistance.27 Over expression of CXCR4 in various cancers have been identified as a 
poor prognostic biomarker. CXCR4 promotes breast cancer metastasis to organs such as bone, 
liver, and lung. In these organs, the ligand, CXCL12, is generated and released in large amounts. 
These organs are most commonly affected by breast cancer metastasis. Various studies have shown 
that the small molecule CXCR4 inhibitors decrease breast cancer metastasis.20 
 
1.3.2 HIV 
Human immunodeficiency virus (HIV) is a virus that attacks the immune system by destroying 
infection fighting white blood cells. HIV type 1 (HIV-1) infection’s virus-cell fusion process is 
the target for development of antagonist drugs.28 CXCR4 was the first co-receptor found to interact 
with HIV-1. Inhibitors such as AMD3100 inhibit HIV-1 at an early stage of the viral life cycle, 
before reverse transcription is initiated.29  
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1.3.3 Auto-immune Diseases 
Rheumatoid arthritis (RA) is an auto-immune disease that causes deformity in the joints caused by 
the immune system attacking the joint tissue. Inflammation in the joints is caused by the infiltration 
of inflammatory cells into the synovial cells.30 Studies shows the CXCR4/CXCL12 axis causes 
the retention of affected synovial tissues in patients and blocking the axis with AMD3100 inhibits 
migration of cells with CXCR4 towards the synovial cells. The results of these studies demonstrate 
that blockage of CXCR4 and CXCL12 interaction plays an important role in accumulation of 
inflammatory cells and the drugs synthesized show a potential for therapeutic treatment for 
patients.31  
 
1.3.4 Inflammation 
Inflammatory bowel disease (IBD) is a chronic inflammatory disease in the gastrointestinal tract. 
IBD consists of Crohn’s disease and ulcerative colitis. CXCR4 and CXCL12 interaction is 
correlated with ulcerative colitis where CXCL12 is highly expressed in the intestinal tissues of the 
patient. In mouse experimental colitis, T cells were found to have high expression level of CXCR4 
and disruption of CXCR4 and CXCL12 interaction alleviates inflammation.32 Studies suggest that 
controlling permeation of inflammatory cells through the CXCR4/CXCL12 axis can be a potential 
therapeutic strategy for ulcerative colitis patients.31 
Allergic asthma is categorized by airflow obstruction, inflammation, high mucus production in 
airway, and bronchial airway hyperresponsiveness (AHR). Chronic inflammation is induced by 
mast cells, followed by Th2 cells and eosinophils into the airways. Th2 cells have shown to express 
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several chemokine receptors including CCR8 and CXCR4, but the CXCR4/CXCL12 axis had only 
been linked to Th2-dependant allergic asthma.31 CXCR4 antagonist drug has shown potential in 
cockroach allergen-induced model where the blockage of CXCR4 and CXCL12 interaction with 
AMD3100 will reduced airway hyperreactivity and eosinophils infiltration.33 
Steroids have been the standard treatment for RA and allergic asthma. However, long-term use of 
steroids leads to side effects and drug resistance. This has promoted the search for alternative 
treatments. Inhibition of this receptor-ligand pair (CXCR4/CXCL12) has been explored as a 
treatment alternative. AMD3100,34-35 and various small peptides36-38 are known to have anti-RA 
activity. However, many of those compounds exhibit poor oral bioavailability and 
pharmacokinetic properties.39 
 
1.4 CXCR4 and Antagonists 
1.4.1 AMD3100 
One of the first small-molecule CXCR4 inhibitor that showed any result was AMD3100 (Figure 
5). AMD3100 is a bicyclam that blocks HIV entry by binding to CXCR4 inhibiting CXCL12.28 It 
is a good antagonist due to its ability to mobilize stem cells and its unique specificity. Other non-
aromatic derivatives of AMD3100 were synthesized and tested for activity but only the compounds 
with the central benzene rings were active.40 
AMD3100 was the first FDA approved small molecule CXCR4 antagonist. Even though this 
compound’s initial purpose was to block HIV-1 entry to the cells, it was given to patients for stem 
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cell mobilization in leukemia patients.41 Due to its cardiotoxic side effects, it was approved for 
limited one time use in patients.42  
 
Figure 5: Structure of AMD3100. 
 
1.4.2 WZ811 
After extensive structure-activity profiling, it was found that for high CXCR4 affinity the central 
aromatic ring is critical. One-carbon separating the central aromatic phenyl ring and the nitrogen 
of acyclic linker is also crucial for high effectiveness.43 The structure activity relationship (SAR) 
studies led to identification of WZ811 as a potential antagonist of CXCR4 (Figure 6).44 Preclinical 
trials showed WZ811 was effective in vitro but ineffective in vivo.45 It also showed poor 
bioavailability due to its rapid oxidative metabolism.  
 
Figure 6: Structure of WZ811. 
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1.4.3 MSX122 
Similar to AMD3100, the center of MSX122 contain a p-xylyl-enediamine center and two 
pyrimidines instead of the cyclam rings (Figure 7). MSX122 was the first CXCR4 inhibitor drug 
to be administered orally.46 It exhibited potent activity in binding affinity assay and in vivo 
functional assays, but the development of the drug was suspended for undisclosed reasons.31  
 
Figure 7: Structure of MSX122. 
 
1.5 Rational for Design 
The process of development of AMD3100 started with development of JM1498 (Figure 8) as a 
potential inhibitor of HIV activity, however it did not show any activity. The drug was embedded 
in an impurity of the two cyclam rings tethered by a direct carbon-carbon linkage, JM1657 (Figure 
8).47 Since JM1657 could not be resynthesized, a project was started to connect the cyclam rings 
using carbon chains. As the carbon chains were increased, an increase in the potency of the drug 
was observed.47 Through clinical trials AMD3100 was found to inhibit HIV-1 and HIV-2 with a 
concentration range of 1-10 nM. This drug was not toxic to the host cells up to the concentration 
of 500 µM.47 When one of the cyclam rings on AMD3100 is replaced with py[iso-14]-ane-N4 ring 
yielding AMD3465 (Figure 8).31 The anti-HIV activity of the drug increased nine fold. AMD3465 
showed efficacy in breast cancer but no other developments have been reported.31  
N
H HN
N
N
N
N
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In later work by Zhu et al., the cyclam rings of AMD3100 were replaced with two pyrimidines to 
synthesize MSX122, which turned out to be a potent compound but the trials were suspended 
without any results (Figure 8).31, 46 MSX122 showed potency in the binding affinity assay and in 
in vitro assays and it was an orally bioavailable compound.31  Whereas, WZ811 does not have oral 
bioavailability and it has a short half-life in the body (Figure 8).22 
  
Figure 8: Progression from JM1498 to MSX122. 
 
AMD3100 and WZ811 both have poor bioavailability which shows that better CXCR4 antagonists 
need to be synthesized. Several analogues have been synthesized by altering the center ring on 
WZ811. Additional structure activity relationship (SAR) studies have been conducted that show 
that for an analogues to be a potent compound and show activity, the center aromatic ring is 
necessary. Modifications in the ring chain can change the structure in shape, size, hydrogen 
bonding, and conformation. These changes may increase stability and lipophilicity and help 
locking structure in place.48 Various modifications cause changes in the receptor binding 
interactions.48 
NH
NH
HN
HN
NH
NH
HN
HN
NH
NH
HN
HNH H
NH
NH
HN
N
N
NH
HN
HN
NH
NH
HN
N H
N N
N
H HN N
NNH HN
N
N
N
N
JM1498 JM1657 AMD3100
AMD3465WZ811MSX122
 
 
 13 
Several studies have been conducted to determine what properties make drugs different from other 
chemicals.49 When designing new analogs, it is important to consider various properties and 
structural components that can potentially lead to a successful drug candidate. The Lipinski rule 
of five is one such consideration. Orally delivered drugs tend to obey the Lipinski’s rule of five.50 
The rule of five has factors that involve numbers that are multiples of five. The rules state that the 
molecular weight of the drug has to be less than 500 g/mol; the drug cannot consist of more than 
5 hydrogen bond donors groups; the drug cannot consist of more than 10 hydrogen bond acceptor 
groups; and the calculated log P value of the drug should be less than +5. Number of hydrogen 
bond donating groups corresponds to the number of amino and hydroxyl groups present in the 
compound. Number of hydrogen bond accepting groups corresponds to the number of nitrogen 
and oxygen molecules present in the compound. Log P is the measurement of the drugs 
hydrophobicity. A drug that consist of two or more traits from the rule of five will most likely have 
poor oral bioavailability. There are exceptions to this rule and those exceptions have been outlined 
by Ghose et al.51 It also suggests that a compound with molecular weight between 180-500 g/mol 
with a log p value between -0.4 and 5.6 will increase the drug-likeness.51  
MSX122 and WZ811 both fall in the molecular weight range of 180-500 g/mol. MSX122 has six 
nitrogen atoms and the log p was calculated to be 1.65.52 Whereas WZ811 has four nitrogen atoms 
and the log p was calculated to be 2.65.52 Since both drug fall in the range of the rule of five, it can 
be inferred that the lower log p value of MZX122 may be one factor that leads to a better oral 
bioavailability. In the past, the p-xylyl-enediamines contain a benzene as the central ring, which 
has a log p of 2.13.53 The benzene ring has been altered to aliphatic chains and aliphatic rings; 
however, these alteration lead to loss of activity.22, 52 
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Our group has focused its research on designing and synthesizing analogues by altering the center 
phenyl ring with other heterocyclic aromatic rings that have a lower lop p value than the phenyl 
ring. Examples of heterocyclic aromatic rings used previously used in our work are furan, 
thiophene, pyrazine, and pyridine (Figure 9). The log p values of the aromatic rings has been listed 
in Table 1. Analogues of furan, thiophene with substituents at 3,4 position, pyrazine, and pyridine 
with substituents at 2,6 position have been synthesized by Dr. Theresa Gaines (Figure 9). 
Analogues of thiophene with substituents at 2,5 positon analogues have been synthesized by 
Francisco Garcia (Figure 9).  
Table 1:Ring Structures and Log P values. 
 
Ring Structure Log P 
Benzene 
 
2.13 
Thiophene 
 
1.81 
Furan 
 
1.34 
Pyridine 
 
0.65 
Pyrazine 
 
-0.26 
Table 1: Values taken from Exploring QSAR53 and Human Metabolome Database.54 
S
O
N
N
N
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In the past, various compounds synthesized have failed biological testing. The reason for this 
failure can be studied by analyzing drug-like pharmacokinetic properties of the compound. 
Pharmacokinetic is the study of absorption, distribution, metabolism, excretion (ADME) and 
toxicity (T) of a drug in the human body.50 For a drug to be absorbed through the gastrointestinal 
tract, it must have the right balance of water and fat solubility. If a drug is too hydrophobic then it 
will fail to be absorbed in the gut and if a drug is too hydrophilic then it will be fail to pass through 
the fatty cell membrane of the gut.50 Distribution of a drug through blood supply is rapid but 
through various tissues and organs is more slowly. Distribution rate also depends on various factors 
such as its physical properties.50 Drug metabolism is when drugs are exposed to enzyme-catalyzed 
reactions which modify the foreign structure so that it can be excreted easily. The modifications 
lower the activity of the drug. These modifications can take place in various tissues but most 
reactions take place in the liver.50 Drug excretion take place through exhaled air, bile, or sweat, 
but most of the excretion takes place through the kidneys.50 Toxicity testing of a drug takes place 
in vitro or in vivo testing to examine for acute or chronic toxicity. During in vivo testing, the mice 
are examined for any presence of carcinogen and individual organs and tissues are analyzed for 
tissue damage. This test is important to determine if a drug should move further in testing and the 
dosage for the initial testing in phase I clinical trials.50 ADMET in silico modeling can be 
conducted for newly designed compounds to determine if the compounds are promising. Lipinski’s 
rule of five should also be considered for compounds that will be orally delivered to identify the 
critical properties. Drugs that have undergo ADMET screening and follow the Lipinski’s rule of 
five therefore have a better chance of succeeding in clinical trials. 
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This current work focuses on analogues of pyridine with substituents at 2,5 position (Figure 9). 
The synthesized analogues will undergo binding affinity assay and Matrigel invasion assay. If the 
results from binding affinity assays are 100 nM and above, the analogues will undergo the Matrigel 
invasion assay. The two biological assays are conducted to test how well the analogues bind to the 
receptors and how effective they are in blocking the receptors. Analogues with the top results from 
Matrigel invasion assay will undergo carrageenan paw edema test. This test is conducted to test 
the anti-inflammatory activity of the analogues. The biological work was conducted at Emory 
University by Dr. Hyunsuk Shim’s Lab. 
 
Figure 9: Progression of CXCR4 antagonists from AMD3100 to analogues synthesized 
by alteration of the center ring and its substituents.  
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2 RESULTS AND DISCUSSION 
2.1 Chemistry  
2.1.1 2,5-diamino pyridine analogues 
Pyridine analogues (3a-3p) were synthesized using reductive amination of 2,5-diamino pyridine 
(1) and a substituted benzaldehyde (2). The analogues were synthesized using two different 
methods (Scheme 1). Method A used sodium triacetoxyborohydride (NaBH(OAc)3) as the 
reducing agent, acetic acid (AcOH) as the catalyst, 1,2-dichloroethane (DCE) as the solvent. 
Method A was used to synthesize compounds 3a-3m. Method B used sodium cyanoborohydride 
(NaBH3CN) as the reducing agent, zinc chloride (ZnCl2) as the catalyst and methanol (MeOH) as 
the solvent. Method B was used to synthesize compounds 3n-3p. Both methods were run over 
night at room temperature.  
 
 
Scheme 1: Synthesis of 2,5-diamono pyridine analogues. 
Method A was used to synthesize 3a-3m and method B was used to synthesize 3n-3p. 
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2.1.2 Synthesis of 2,5-dicarbaldehyde pyridine 
The starting material 2,5-dicarbaldehyde pyridine (5) was synthesized by reduction of ester to 
aldehyde (Scheme 2).  
 
Scheme 2: Synthesis of 2,5-dicarbaldehyde pyridine. 
 
2.1.3 2,5-dicarbaldehyde pyridine analogues 
Pyridine analogues (7a-7p) were synthesized using reductive amination of 2,5-diamino pyridine 
(5) and a substituted aniline (6). The analogues were synthesized using sodium 
triacetoxyborohydride (NaBH(OAc)3) as the reducing agent, acetic acid (AcOH) as the catalyst, 
and 1,2-dichloroethane (DCE) as the solvent (Scheme 3). 
 
Scheme 3: Synthesis of 2,5-dicarbaldehyde pyridine analogues. 
 
2.2 Biology 
Our collaborators from Dr. Hyunsuk Shim’s lab at Emory University performed all the biological 
assays. 
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2.2.1 Binding Affinity Assay 
All pyridine analogues are initially screened with binding affinity assay. For this assay, MDA-
MB-231 breast cells are used along with TN14003, a biotinylated peptide known CXCR4 inhibitor, 
and rhodamine conjugated streptavidin, used for florescence of cells. The cells are incubated with 
the analogues at 1, 10, 100, and 1000 nM concentrations. These cells are then incubated with the 
inhibitor followed by streptavidin. The florescence of the cells is measured to obtain effective 
concentration. Effective concentration (EC) of the compound is the lowest concentration at which 
is a reduction of florescence is significant compared to the positive control. Any analogues that 
have an EC of 100 nM or lower are then subjected to Matrigel invasion assay.  
 
2.2.2 Matrigel Invasion Assay  
Matrigel invasion assay is used as a functional assay to probe if the synthesized analogues can 
block CXCR4/CXCL12 mediated chemotaxis and invasion. A two chambered apparatus is used 
for this assay where the top chamber consists of MDA-MB-231 breast cancer cells incubated in 
100 nM concentration of the analogues and the bottom chamber consist of CXCL12 as a 
chemoattractant as shown in Figure 10. The partition between the two chambers is the Matrigel 
matrix through which the cells can pass. The percentage of inhibition of chemotaxis compared to 
the control is the measurement that is acquired from this assay. At the end of the assay, the number 
of cells that migrated through the matrix, from the top chamber to the bottom chamber, are counted. 
The number of cell that were inhibited from passing through the matrix are compared to the 
negative control. This is the percent inhibition of the analogue. These results indicate that a 
stronger inhibitor would allow the least number of cell to pass through the matrix. 
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The analogues that showed potential in the binding affinity assay, in other words the compounds 
that had an EC of 100 nM or lower, were the ones to be tested for Matrigel invasion assay. An 
invasion inhibition of 35% or greater were preferential. The results for this assay for both sets of 
analogues along with the results of binding affinity assay are stated in Tables 2 and 3 . AMD3100 
and WZ811 were used as benchmarks for comparison to the analogues. The results for AMD 3100 
and WZ811 for both assays are also listed in the tables. 
 
Figure 10: Two chamber apparatus used for Matrigel invasion assay. 
 
2.2.3 Carrageenan Paw Edema Test 
Carrageenan paw edema test is used to test if the analogues possess anti-inflammatory activity in 
vivo. CXCR4 has shown to play a key role in recruit inflammatory cells to inflammation sites.43 
Based on the results of the analogues in vitro, the best analogues are sent for testing the in vivo 
carrageenan paw edema test. If a Matrigel invasion assay is conducted with the analogues and the 
inhibition is more than a 50%, then a paw test is conducted using those analogues. This test can 
also be used as a preliminary screen of the toxicity of the analogue based on the health of the mice 
during and after the test.  
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For this test, both of the hind paws of the mice are inflamed by insertion of carrageenan. An 
injection of saline solution is inserted in one paw where as an injection of the analogue solution is 
inserted in the other. At the end of the test, both paws are measured using a caliper to determine 
the decrease in swelling. The percentage is calculated comparing the reduction in inflammation of 
one paw to the other. Analogues that had a score of 100 nM or lower in binding affinity assay and 
an inhibition of 50% in Matrigel invasion assay are considered to be hit compounds. These are 
sent for further testing, paw edema test. From all the compounds, eleven qualified and the top one 
from each set (3l and 7c) was sent for testing. Results are shown in Table 6. 
 
2.3 Assay Results 
Three biological tests were conducted to determine if the analogues synthesized are viable as small 
molecule CXCR4 antagonists. Binding affinity assay was used as the preliminary test to determine 
the potency of the compound. Matrigel invasion assay was important to see if the compound 
ingibit6ed chemotaxis. Carrageenan paw edema test was to see how the compounds did in in vivo 
testing. From all the compounds, twelve showed good activity in the binding affinity and the 
Matrigel invasion assays, and eleven of those were considered to be hit compounds. The top two 
of the eleven compounds were send for carrageenan testing. The results for both 2,5-diamino 
pyridine analogues and 2,5-dicarbaldehyde pyridine analogues for binding affinity and Matrigel 
invasion assays are listed in Tables 2 and 3, respectively. The results for carrageenan paw edema 
test are listen in Table 6. WZ811 is used as a benchmark molecule because of its reduction in 
inflammation by 40%. 
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Table 2: Results for Binding affinity assay and Matrigel invasion assay for 2,5-diamino pyridine 
analogues (3). 
 
Compound R Group EC (nM) Inhibition Compound R Group EC (nM) Inhibition 
3a H 1000 ---- 3i 2-F 100 53% 
3b 2-Me 100 82% 3j 3-F 100 5% 
3c 3-Me 100 50% 3k 4-F 1000 ---- 
3d 4-Me 10 36% 3l 4-Cl 10 84% 
3e 4-Et >1000 ---- 3m 4-Br 1000 ---- 
3f 2-OMe >1000 ---- 3n 2-NO2 1000 ---- 
3g 3-OMe >1000 ---- 3o 3-NO2 1000 ---- 
3h 4-OMe 1000 ---- 3p 4-NO2 1000 ---- 
AMD3100 ---- 1000 62% WZ811 ---- 10 90% 
In the 2,5-diamino pyridine analogues (Table 2), six performed well in biding affinity assay and 
five out of those six compounds performed well in Matrigel invasion assay. Three out of the five 
contained methyl as the R-group (3b-3d). The other two compounds contained a halogen as an R-
group, fluorine (3i) and chlorine (3l). Out of all the compounds, the electron withdrawing groups 
do not seem to show any favorable activity, such as the nitro groups. The best compounds in 
binding affinity assay were 4-Me (3d) and 4-Cl (3l) with an effective concentration of 10 nM. In 
Matrigel invasion assay 3d had a inhibition of 36%, whereas 3l had an invasion inhibition of 84%. 
When compared to AMD3100 and WZ811, 3l did well and can be considered a potent compound 
for additional testing in vivo. The 2-Me (3b) and 3-Me (3c) showed an effective concentration of 
N
H
N
N
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100 nM and an invasion inhibition of 82% and 50%, respectively. Of the fluoro R-groups, 4-F (3k) 
showed no activity at 1000 nM but 2-F (3i) and 3-F (3j) showed a favorable activity at 100 nM 
and an invasion inhibition of 53% and 5% respectively. Compound 3j would not be considered a 
hit compound because it does not inhibit the cells from migrating through the matrix effectively. 
Although there is no specific trend of activity correlated to the structure of these compounds there 
seems to be general trend that smaller substituents, such as methyl, fluoro, and chloro, are preferred 
over larger substituents, such as ethyl, methoxy, and nitro. These results could suggest how the  
compounds fit into the active cite of CXCR4. Docking studies can be done to observe the 
interaction of the compound with residues in the active site.  
Table 3: Results for Binding affinity assay and Matrigel invasion assay for 2,5-dicarbaldehyde 
pyridine analogues (7). 
 
Compound R Group EC (nM) Inhibition Compound R Group EC (nM) Inhibition 
7a H 1000 ---- 7i 2-F 1000 ---- 
7b 2-Me 1000 ---- 7j 3-F 100 82% 
7c 3-Me 1 99% 7k 4-F 1000 ---- 
7d 4-Me 100 85% 7l 4-Cl 1000 ---- 
7e 4-Et 1000 ---- 7m 4-Br 1000 ---- 
7f 2-OMe 100 84% 7n 2-NO2 1000 ---- 
7g 3-OMe 100 77% 7o 3-NO2 100 73% 
7h 4-OMe 1000 ---- 7p 4-NO2 1 80% 
AMD3100 ---- 1000 62% WZ811 ---- 10 90% 
N N
HHN
R
R
7
 
 
 24 
In the 2,5-dicarbaldehyde pyridine analogues (Table 3), seven analogues performed well in both 
biding affinity assay and in Matrigel invasion assay. Of the methyl R-groups, 2-Me (7b) showed 
no activity at EC of 1000 nM but 3-Me (7c) and 4-Me (7d) showed a favorable activity with an 
effective concentration at 1 nM and 100 nM and an invasion inhibition of 99% and 85%, 
respectively. Of the methoxy R-groups, 4-OMe (7h) showed no activity but 2-OMe (7f) and 3-
OMe (7g)  showed a favorable activity at an EC of 100 nM and invasion inhibition of 84% and 
77%, respectively. Only 3-F (7j) showed activity at an EC of 100 nM and an inhibition of 82%. 
Of the nitro R-groups, 2-NO2 (7n) showed no activity at EC of 1000 nM but 3-NO2 (7o) and 4-
NO2 (7p) showed a favorable activity at an EC of 100 nM and 1 nM and invasion inhibition of 
73% and 80%, respectively. The best compounds were 7c and 7p at EC of 1 nM and invasion 
inhibition of 99% and 80%. Compared to AMD3100 and WZ811, both compounds did well and 
can be considered potent compounds pending the results of the carrageenan paw edema test results. 
Furthermore, when the structure is switched from the nitrogen (3) is attached to the center ring to 
this one (7), the larger substituents can be accommodated that was not accommodated in the first 
set. 
The 2,5-diamino pyridine analogues (3) and 2,5-dicarbaldehyde pyridine analogues (7) are 
constitutional isomers. Comparing the two analogues show how connectivity makes a difference 
in activity of the compound in vitro tests. There were several similarities and difference in terms 
of which compounds showed activity. Some R-groups such as hydrogen, ethyl, and bromine 
showed no favorable activity in either set of analogues. Similarly methoxy and fluoro at the ortho 
position, and nitro at the para position did not show any favorable activity in either set of 
analogues. Seven R-groups exhibited activity in only one of the set of analogues. In 2,5-diamino 
pyridine analogues, 2-Me (3b) and 2-F (3i) had favorable activity at EC of 100 nM with an invasion 
 
 
 25 
inhibition of 82% and 53%, respectively and 4-Cl (3l) had favorable activity at EC of10 nM with 
an invasion inhibition of 84%. When 2-Me, 2-F, and 4-Cl in 2,5-dicarbaldehyde pyridine 
analogues (7b, 7i, and 7l) are compared, they showed no favorable activity at EC of 1000 nM. In 
2,5-dicarbaldehyde pyridine analogues, 2-OMe (7f), 3-OMe (7g), and 3-NO2 (7o) had a favorable 
activity at 100 nM effective concentration with an invasion inhibition of 84%, 77%, and 73%, 
respectively, and 4-NO2 (7p) had an EC of 1 nM and invasion inhibition of 80%. When 2-OMe, 
3-OMe, 3-NO2, and 4-NO2 in 2,5-diamino pyridine analogues (3f, 3g, 3o, and 3p) are compared, 
they show no favorable activity at EC of 1000 nM. Three compounds exhibited activity in both 
sets of analogues; 3-Me, 4-Me, and 3-F. Comparing the two analogues shows an increase or 
decrease in activity of the compound in the cells. When both sets of analogues are compared, it 
can be noticed that when the carbon is attached to the center ring, the activity of the compound 
increases significantly, at least by 45%. This shows that just changing how the center ring is 
connected to the side chain can make a different in how the compound interacts with CXCR4.  
A similar set of pyridine compounds were synthesized and analyzed by Dr. Theresa Gaines. The 
results of these compounds were published (Table 4).55 The center ring of this compound is a 
pyridine with substituents attached at 2 and 6 position. An R-group of 3-Me had a favorable 
activity in all three analogues (3c, 7c, and 8c). 8c had an invasion inhibition of 60% at EC of 100 
nM. Changing the position of substituents from 2,6 (8c) to 2,5 (7c) increases the activity to 99% 
invasion inhibition with a 100-fold improvement in effective concentration, whereas changing the 
position of substituents and connecting the center ring to a nitrogen first (3c) decreases the activity 
to 50% invasion inhibition. An R-group of 3-F had a favorable activity in all three analogues (3j, 
7j, and 8g). 8g had an invasion inhibition of 50% at EC of 10 nM. Changing the position of 
substituents from 2,6 (8g) to 2,5 (7j) increases the activity 32% with a decline in effective 
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concentration 10-fold, whereas changing the position of substituents and connecting the center 
ring to a nitrogen first (3j) decreases the activity 45% with a decline in concentration 10-fold. 
Comparing the 2-OMe R-group, activity increases from <1% to 84% when the position of 
substituents are switched from 2,5 to 2,6 (8j and 7f). Likewise the activity for 3-OMe R-group 
increases from 37% to 77% (8k and 7g). Comparing the 4-Cl R-group, activity increases from 
21% to 84% when the position of substituents are switched from 2,5 to 2,6 and the center ring is 
attached to nitrogen first (8i and 3l). No activity is observed when any changes are made to 
structure analogues with R-group of 4-Et (8e), 4-F (8h), and 4-OMe (8l). 
Table 4: Results for Binding affinity assay and Matrigel invasion assay for 2,6-dicarbaldehyde 
pyridine analogues. 
 
Compound R Group EC (nM) Inhibition Compound R Group EC (nM) Inhibition 
8a  H 100 <1% 8h 4-F 100 5% 
8b 2-Me >1000 ---- 8i 4-Cl 100 21% 
8c 3-Me 100 60% 8j 2-OMe 1000 <1% 
8d 4-Me 1000 ---- 8k 3-OMe 100 37% 
8e 4-Et 1 64% 8l 4-OMe 100 5% 
8f 2-F 1000 ---- 8m 3-NO2 >1000 ---- 
8g 3-F 10 50% 8n 4-NO2 >1000 --- 
Table 4: All compounds in this table were synthesized by Dr. Theresa Gaines 55 which will be analyzed in 
the discussion section of this work. 
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A set of compounds were synthesized by Weiqiang Zhan. The results were previously published 
(Table 5).22 When comparing the dialdehyde analogues (9) to 2,5-dicarbaldehyde pyridine 
analogues (7), the only difference is that the 9 analogues contain a phenyl ring and newly 
synthesized analogues (7) contain a pyridine ring in the center. While 4-Me (7d) and 2-OMe (7f) 
were only 10-fold less active, 4-OMe (7h) and 4-Et (7e) were 40-fold less active, and 3-OMe (7g) 
and 3-NO2 (7o) were 100 fold less active, and 2-F (7i) did not block the chemokine at all. 
Surprisingly, there was a 1000-fold improvement in 4-NO2 (7p) analogue. It cannot be determined 
if the analogues improved in inhibiting the cells from invading through the matrix, as the invasion 
inhibition data is unavailable. In conclusion, changing the center ring from phenyl to pyridine 
decreased the overall activity of the compounds in binding affinity assay. 
Table 5: Results for Binding affinity assay for 1,4-benzaldehyde analogues. 
 
Compound R Group EC (nM) Compound R Group EC (nM) 
9a  4-NO2 1000 9f 3-F 100 
9b 4-F 1000 9g 3-NO2 1 
9c 4-OMe 25 9h 3-OMe 1 
9d 4-Me 10 9i 2-F 1 
9e 4-Et 20 9j 2-OMe 10 
Table 5: All compounds in this table were synthesized by Weiqiang Zhan 22 which will be analyzed in the 
discussion section of this work. 
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Of note, the structure of the previously reported small molecule antagonists of CXCR4 such as 
AMD3100, WZ811, and MSX122 are most similar to that of the 2,5-dicarbaldehye pyridine 
analogues (7). One major difference between these two sets of compounds is that AMD 3100, 
WZ811, and MSX 122 have benzene as a center ring, whereas, the newly synthesized analogues 
have a pyridine as the center ring. The position of the side chains in the 2,5 position of compound 
7 is similar to that of these previously reported molecules. The position is significant because even 
though the 2,6-pyridine analogues (8) are symmetrical (Table 3), they show lower activity in the  
Matrigel invasion assay than the 2,5-pyridine analogues (7). It can be inferred that the position of 
the substituents plays a critical role in the binding of these small molecules in the active site and 
inhibiting the invasion of cells.  The 2,5 position analogues would be an appropriate starting point 
for exploration of future potent compounds. 
 
Table 6 shows the results for carrageenan paw test for two compounds. Two compounds that were 
showed some of the highest activity in the binding affinity assay and the invasion assay were sent 
for testing, which were 3l and 7c. Both compounds showed no significant reduction in 
inflammation of the mice paw. The 2,5-diamino analogue with 4-Cl as R-group (3l) showed a 
reduction of inflammation of 8% and the 2,5-dicarbaldehyde pyridine with 3-Me as the R-group 
(7c) showed no reduction of inflammation. This result could be due to the compound metabolizing 
at a high rate in the mice’s body, which in turn changes the structure of the compound reducing 
the effects on inflammation. the small molecule metabolizing too quickly in vivo, thereby making 
it less effective. Further pharmacokinetic studies are needed to confirm the metabolism rate for 
these compounds.  
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Table 6: Results for Carrageenan Paw Edema Test. 
 
Compound R Group EC (nM) Inhibition 
of invasion 
Reduction of 
inflammation 
3l 4-Cl 10 84% 8% 
7c 3-Me 1 99% ---- 
AMD3100 ---- 1000 62% ---- 
WZ811 ---- 10 90% 40% 
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3 CONCLUSIONS 
CXCR4 antagonist were synthesized via reductive amination. A small library of pyridine 
analogues were synthesized with substituents at 2,5 position were synthesized and analyzed for 
purity using NMR, MS and melting point. These analogues also went through several biological 
tests including binding affinity assay, Matrigel invasion assay, carrageenan paw edema test to test 
for potential CXCR4 inhibitors.  
Overall the 2,5-dicarbaldehyde pyridine analogues (Table 3) gave better results than 2,5-diamino 
pyridine analogues (Table 2). For the binding affinity assay, several compounds from both sets of 
analogues had an effective concentration of 100 nM or less. These compounds were sent for 
Matrigel invasion assay. If the analogues had an invasion 50% or higher, they were considered to 
be hit compounds. The compounds that performed best in the preliminary assays will be subjected 
to the carrageenan paw edema test. 
For 2,5-diamino pyridine analogues, compounds with smaller substituents such as methyl, chloro, 
and fluoro had more activity in the assays than compounds with bigger substituents such as ethyl, 
methoxy, bromo, and nitro. The best compound was 4-Cl (3l); this compound is has been submitted 
to our collaborators for the carrageenan paw edema test. For 2,5-dicarbaldehyde pyridine 
analogues, compounds with longer substituents such as methyl, methoxy, and nitro showed more 
activity in the assays than compounds with smaller substituents such as fluoro, chloro, and bromo. 
The best compound was 3-Me (7c); this compound was also sent for carrageenan paw edema test.  
There are several ways to extend this library. Compounds with an R-group of trifluoromethyl, 
cyano, thiomethoxy, and ethoxy can be synthesized at various positions. Non-aromatic R-groups 
such as morpholine, thiomorpholine, pyrrolidine, and 1-methylpiperazine, can also be used. 
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Furthermore, chlorine at meta and othro positions can be synthesized for 2,5-diamino pyridine 
analogue to compare to para chlorine analogue (3l). Another way to extend the library is to test the 
theory of compound with a smaller side chain showing more potency of being a CXCR4 inhibitor 
verses longer side chains. This can be tested by adding a longer substituents such as isopropyl and 
butyl and comparing it to how well methyl and ethyl did in biological assays. Computational 
studies in silico could also be used to predict ADMET properties such as – solubility, permeability, 
absorption, cytochrome p450 metabolism, and toxicity. 
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4 EXPERIMENTAL 
4.1 Chemistry 
The 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra were recorded on a Bruker Ac 400 FT 
NMR spectrometer in deuterated chloroform (CDCl3). All chemical shifts were reported using 
parts per million (ppm). Mass spectra were recorded on a JEOL spectrometer at Georgia State 
University Mass Spectrometry Center. 
 
4.1.1 General procedure for synthesis of 2,5-diamino pyridine analogues (3) 
Method A: To a solution of 2,5-diamino pyridine (50 mg), in 1,2-dichloroethane (4.6 mL), 
benzaldehyde derivative (2.5 eq) and acetic acid (2 eq) were added. After stirring for 5 min at room 
temperature, the solution was treated with sodium triacetoxyborohydride (3 eq). It was then stirred 
at room temperature overnight and purified via preparative thin layer chromatography. This 
method was used to synthesis compounds 3a-3m. 
 
Method B: To a solution of 2,5-diamino pyridine (50 mg), in methanol (4.6 mL), benzaldehyde 
derivative (2.5 eq) and zinc chloride (2 eq) were added. After stirring for 5 min at room 
temperature, the solution was treated with sodium cyanoborohydride (3 eq). It was then stirred at 
room temperature overnight. Methanol was evaporated using reduced pressure. Crude compound 
was dissolved in ethyl acetate  and purified via preparative thin layer chromatography. This method 
was used to synthesize compounds 3n-3p. 
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N2,N5-Dibenzylpyridine-2,5-diamine (3a). 7% yield as yellow solid; MP: 90-91°C. 1H NMR 
(400 MHz, CDCl3): δ ppm 7.64 (br. s., 1H), 7.18 - 7.43 (m, 10H), 6.86 (d, J = 8.59 Hz, 1H), 6.29 
(d, J = 8.59 Hz, 1H), 4.41 (br. s., 2H), 4.23 (br. s., 2H). 13C NMR (100 MHz, CDCl3): δ ppm 152.4, 
139.7, 139.3, 136.74, 133.4, 128.6, 127.4, 124.9, 107.5, 49.5, 47.1. HRMS: m/z [M + H]+ calcd 
for C19H20N3: 290.1652, found: 290.1640. 
 
N2,N5-Bis(2-methylbenzyl)pyridine-2,5-diamine (3b). 6% yield as yellow oil. 1H NMR (400 
MHz, CDCl3): δ ppm 7.66 (d, J = 2.53 Hz, 1H), 7.32 (d, J = 3.28 Hz, 2H), 7.14 - 7.21 (m, 6H), 
6.91 (dd, J = 2.78, 8.84 Hz, 1H), 6.33 (d, J = 8.59 Hz, 1H), 4.39 (s, 2H), 4.20 (s, 2H), 2.32 - 2.39 
(m, 6H). 13C NMR (100 MHz, CDCl3): δ ppm 152.4, 136.93, 132.5, 130.4, 128.1, 127.2, 126.1, 
125.1, 107.6, 47.5, 45.1, 18.9. HRMS: m/z [M + H]+ calcd for C21H24N3: 318.1965, found: 
318.1965. 
 
N2,N5-Bis(3-methylbenzyl)pyridine-2,5-diamine (3c). 7% yield as white solid; MP: 95-95°C . 
1H NMR (400 MHz, CDCl3): δ ppm  7.64 (d, J = 2.53 Hz, 1H), 7.10 - 7.26 (m, 6H), 7.00 - 7.10 
(m, 2H), 6.86 (dd, J = 2.65, 8.72 Hz, 4H), 6.28 (d, J = 8.84 Hz, 4H), 4.36 (s, 2H), 4.17 (s, 2H), 
2.32 (d, J = 4.29 Hz, 6H). 13C NMR (100 MHz, CDCl3): δ ppm 152.5, 139.6, 138.1, 133.3, 
128.3, 124.6, 107.4, 49.4, 47.1. HRMS: m/z [M + H]+ calcd for C21H23N3: 317.1965, found: 
318.1951. 
 
N2,N5-Bis(4-methylbenzyl)pyridine-2,5-diamine (3d). 8% yield as pale yellow solid; MP: 142-
144°C. 1H NMR (400 MHz, CDCl3): δ ppm 7.65 (br. s., 1H), 7.24 (d, J = 8.28 Hz, 4H), 7.07 - 7.19 
(m, 4H), 6.88 (d, J = 8.66 Hz, 1H), 6.30 (d, J = 8.66 Hz, 1H), 4.37 (s, 2H), 4.20 (s, 2H), 2.33 (s, 
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6H). 13C NMR (100 MHz, CDCl3): δ ppm 152.5, 136.7, 133.4, 129.3, 127.4, 124.9, 107.5, 49.3, 
46.9. HRMS: m/z [M + H]+ calcd for C21H23N3: 318.1970, found: 318.1982. 
 
N2,N5-Bis(4-ethylbenzyl)pyridine-2,5-diamine (3e). 10% yield as pale yellow solid; MP: 112-
113°C . 1H NMR (400 MHz, CDCl3): δ ppm 7.66 (d, J = 2.53 Hz, 1H), 7.23 - 7.30 (m, 4H), 7.16 
(dd, J = 4.67, 7.96 Hz, 4H), 6.88 (dd, J = 2.91, 8.72 Hz, 1H), 6.31 (d, J = 8.59 Hz, 1H), 4.39 (br. 
s., 2H), 4.20 (s, 2H), 2.63 (dd, J = 2.02, 7.58 Hz, 4H), 1.22 (dd, J = 1.77, 7.58 Hz, 6H). 13C NMR 
(100 MHz, CDCl3): δ ppm 152.5, 143.4, 137.2, 136.9, 133.8, 128.4, 127.9, 125.2, 107.8, 49.6, 
47.3, 28.8, 15.8. HRMS: m/z [M + H]+ calcd for C23H28N3: 346.2283, found: 346.2256. 
 
N2,N5-Bis(2-methoxybenzyl)pyridine-2,5-diamine (3f). 9% yield as yellow oil. 1H NMR (400 
MHz, CDCl3): δ ppm 7.66 (br. s., 1H), 7.18 - 7.34 (m, 4H), 6.82 - 6.98 (m, 5H), 6.33 (d, J = 8.84 
Hz, 1H), 4.40 (br. s., 2H), 4.23 (s, 2H), 3.83 (br. s., 6H). 13C NMR (100 MHz, CDCl3): δ ppm 
157.7, 153.1, 137.1, 134.4, 129.1, 128.4, 125.6, 120.8, 110.5, 107.7, 55.6, 45.5, 42.9. HRMS: m/z 
[M + H]+ calcd for C21H24N3O2: 350.1863, found: 350.1848. 
 
N2,N5-Bis(3-methoxybenzyl)pyridine-2,5-diamine (3g). 11% yield as yellow solid; MP: 99-
101°C. 1H NMR (400 MHz, CDCl3): δ ppm 7.64 (d, J = 2.27 Hz, 1H), 7.16 - 7.31 (m, 2H), 6.84 - 
6.98 (m, 5H), 6.75 - 6.83 (m, 2H), 6.30 (d, J = 8.59 Hz, 1H), 4.40 (s, 2H), 4.22 (s, 2H), 3.78 (d, J 
= 4.80 Hz, 6H). 13C NMR (100 MHz, CDCl3): δ ppm 159.8, 152.4, 141.0, 136.7, 133.2, 129.5, 
124.9, 119.6, 112.9, 107.6, 60.4, 55.1, 49.4, 47.1. HRMS: m/z [M + H]+ calcd for C21H24N3O2: 
350.1863, found: 350.1849. 
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N2,N5-Bis(4-methoxybenxyl)pyridine-2,5-diamine (3h). 15% yield as clear oil. 1H NMR (400 
MHz, CDCl3): δ ppm 7.67 (d, J = 2.53 Hz, 1H), 7.33 (d, J = 6.57 Hz, 2H), 7.15 - 7.22 (m, 6H), 
6.91 (dd, J = 2.78, 8.84 Hz, 1H), 6.33 (d, J = 8.59 Hz, 1H), 4.40 (s, 2H), 4.21 (s, 2H), 2.33 - 2.39 
(m, 6H). 13C NMR (100 MHz, CDCl3): δ ppm 158.6, 152.2, 136.3, 132.6, 131.0, 129.6, 128.3, 
1245.0, 113.6, 107.3, 55.0, 46.7, 46.3. HRMS: m/z [M + H]+ calcd for C21H24N3O2: 350.1863, 
found: 350.1849. 
 
N2,N5-Bis(2-fluorobenzyl)pyridine-2,5-diamine (3i). 13% yield as yellow oil. 1H NMR (400 
MHz, CDCl3): δ ppm 7.55 (d, J = 2.78 Hz, 1H), 7.30 - 7.41 (m, 2H), 7.18 - 7.27 (m, 2H), 6.99 - 
7.11 (m, 4H), 6.96 (dd, J = 2.78, 8.84 Hz, 1H), 6.36 (d, J = 8.84 Hz, 1H), 4.48 (s, 2H), 4.29 (s, 
2H). 13C NMR (100 MHz, CDCl3): δ ppm 152.3, 136.5, 131.1, 129.8, 129.6, 129.0, 127.2, 126.6, 
126.1, 124.5, 115.6, 108.2, 43.5, 40.6. HRMS: m/z [M + H]+ calcd for C19H18N3F2: 326.1463, 
found: 326.1449. 
 
N2,N5-Bis(3-fluorobenzyl)pyridine-2,5-diamine (3j). 8% yield as yellow solid; MP: 63-64°C. 1H 
NMR (400 MHz, CDCl3): δ ppm 7.62 (d, J = 2.78 Hz, 1H), 7.23 - 7.32 (m, 2H), 7.12 (d, J = 7.58 
Hz, 2H), 7.03 - 7.09 (m, 2H), 6.94 (dq, J = 2.15, 8.13 Hz, 2H), 6.86 (dd, J = 2.91, 8.72 Hz, 2H), 
6.29 (d, J = 8.59 Hz, 1H), 4.44 (s, 2H), 4.26 (s, 2H). 13C NMR (100 MHz, CDCl3): δ ppm 164.3, 
161.9, 152.2, 142.6, 142.2, 136.5, 133.5, 129.9, 124.9, 122.7, 114.0, 107.7, 48.9, 46.5. HRMS: m/z 
[M + H]+ calcd for C19H18N3F2: 326.1463, found: 326.1463. 
 
N2,N5-Bis(4-fluorobenzyl)pyridine-2,5-diamine (3k). 12% yield as pale yellow solid; MP: 137-
138°C. 1H NMR (400 MHz, CDCl3): δ ppm 7.62 (d, J = 2.27 Hz, 1H), 7.30 (t, J = 5.81 Hz, 19H), 
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7.00 (q, J = 8.34 Hz, 18H), 6.86 (dd, J = 2.78, 8.84 Hz, 5H), 6.29 (d, J = 8.59 Hz, 5H), 4.38 (s, 
10H), 4.20 (s, 9H). 13C NMR (100 MHz, CDCl3): δ ppm 162.90, 160.5, 152.0, 136.3, 134.7, 136.3, 
133.0, 128.6, 124.6, 115.2, 107.3, 48.4, 45.9. HRMS: m/z [M + H]+ calcd for C19H17N3F2: 
326.1463, found: 326.1468. 
 
N2,N5-Bis(4-chlorobenzyl)pyridine-2,5-diamine (3l). 15% yield as orange solid; 150-151°C. 1H 
NMR (400 MHz, CDCl3): δ ppm 7.62 (br. s., 1H), 7.27 - 7.32 (m, 8H), 6.85 (d, J = 8.59 Hz, 1H), 
6.28 (d, J = 8.84 Hz, 1H), 4.41 (br. s., 2H), 4.23 (s, 2H). 13C NMR (100 MHz, CDCl3): δ ppm 
152.3, 138.3, 137.8, 136.6, 133.4, 128.6, 124.9, 107.7, 48.8, 46.3. HRMS: m/z [M + H]+ calcd for 
C19H18N3Cl2: 358.0872, found: 358.0862. 
 
N2,N5-Bis(4-bromobenzyl)pyridine-2,5-diamine (3m). 16% yield as orange solid; MP: 157-
159°C. 1H NMR (400 MHz, CDCl3): δ ppm 7.61 (br. s., 1H), 7.38 - 7.49 (m, 4H), 7.17 - 7.29 (m, 
6H), 6.84 (d, J = 8.59 Hz, 1H), 6.27 (d, J = 8.59 Hz, 1H), 4.39 (br. s., 2H), 4.21 (s, 2H). 13C NMR 
(100 MHz, CDCl3): δ ppm 152.2, 138.9, 138.4, 136.5, 133.4, 131.6, 129.0, 124.9, 120.8, 107.7, 
48.8, 46.4. HRMS: m/z [M + H]+ calcd for C19H18N3Br2: 445.9862, found: 445.9850. 
 
N2,N5-Bis(2-nitrobenzyl)pyridine-2,5-diamine (3n). 12% yield as yellow oil. 1H NMR (400 
MHz, CDCl3): δ ppm 8.05 - 8.12 (m, 1H), 7.96 - 8.01 (m, 1H), 7.61 (d, J = 4.55 Hz, 4H), 7.41 - 
7.52 (m, 2H), 7.26 - 7.34 (m, 1H), 7.17 - 7.22 (m, 1H), 6.64 - 6.70 (m, 1H), 4.76 (s, 2H), 4.55 (s, 
2H). 13C NMR (100 MHz, CDCl3): δ ppm 150.1, 138.7, 135.7, 135.2, 134.8, 131.1, 130.4, 129.9, 
129.6, 126.5, 46.5, 44.9. HRMS: m/z [M + H]+ calcd for C19H18N5O4: 380.1353, found: 380.1337. 
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N2,N5-Bis(3-nitrobenzyl)pyridine-2,5-diamine (3o). 9% yield as orange solid; MP: 135-137°C. 
1H NMR (400 MHz, CDCl3): δ ppm 8.22 (d, J = 10.11 Hz, 2H), 8.06 - 8.15 (m, 2H), 7.69 (t, J = 
6.69 Hz, 2H), 7.58 (d, J = 3.03 Hz, 1H), 7.49 (dd, J = 7.86, 12.82 Hz, 2H), 6.87 (dd, J = 2.91, 8.72 
Hz, 1H), 6.33 (d, J = 8.84 Hz, 1H), 4.58 (br. s., 2H), 4.39 (s, 2H). 13C NMR (100 MHz, CDCl3): δ 
ppm 142.4, 133.4, 133.2, 129.6, 129.4, 125.2, 122.4, 122.1, 108.2, 48.7, 46.0. HRMS: m/z [M + 
H]+ calcd for C19H18N5O4: 380.1359, found: 380.1339. 
 
N2,N5-Bis(3-nitrobenzyl)pyridine-2,5-diamine (3p). 4% yield as orange solid; 168-170°C. 1H 
NMR (400 MHz, CDCl3): δ ppm 8.18 (dd, J = 8.72, 10.99 Hz, 4H), 7.46 - 7.64 (m, 4H), 6.84 (dd, 
J = 2.91, 8.72 Hz, 1H), 6.30 (d, J = 8.59 Hz, 1H), 4.58 (s, 2H), 4.40 (br. s., 2H). 13C NMR (100 
MHz, CDCl3): δ ppm 151.6, 147.7, 146.8, 135.9, 132.9, 127.4, 124.6, 123.6, 107.7, 48.3, 45.7. 
HRMS: m/z [M + H]+ calcd for C19H18N5O4: 380.1359, found: 380.1339. 
 
4.1.2 Procedure for synthesis of 2,5-dicarbaldehyde pyridine (5) 
Synthesis was carried out using procedure mentioned elsewhere.56 Dimethyl-2,5-pyridine 
dicarbaldehye (5 g) in dry dichloromethane (50 mL) was put under nitrogen and cooled to -78 °C. 
Di-isobutyl aluminum hydride (1M in toluene, 2.5 eq) was added dropwise to the solution. The 
reaction mixture was run for 1 hour at -78 °C and quench with sodium tartrate solution, extracted 
with ethyl acetate (3 X 15 mL), washed with deionized water and brine, dried with magnesium 
sulfate, filtered and concentrated under reduced pressure. Crude product was purified by column 
chromatography (1:1 Hexane/Ethyl acetate). Pale yellow product was obtained in 39% yield. 1H 
NMR (400 MHz, CDCl3): δ ppm 10.24 (s, 1H), 10.18 (s, 1H), 9.25 (s, 1H), 8.36 (dd, J = 0.88, 7.96 
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Hz, 1H), 8.13 (d, J = 8.08 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ ppm 192.4, 189.9, 156.0, 
151.9, 137.3, 133.6, 121.8.  
 
4.1.3 General procedure for synthesis of 2,5-dicarbaldehyde pyridine analogues (7) 
To a solution of 2,5-dicarbaldehyde pyridine (50 mg), in 1,2-dichloroethane (3.6 mL), aniline 
derivative (6 eq) and acetic acid (2 eq) were added. After stirring for 5 min at room temperature, 
the solution was treated with sodium triacetoxyborohydride (3 eq). It was then stirred at room 
temperature overnight and purified via preparative thin layer chromatography. 
 
2,5-Bis(anilinomethyl)pyridine (7a). 9% yield as yellow oil; MP: 111-112°C . 1H NMR (400 
MHz, CDCl3): δ ppm 8.58 (s, 1H), 7.65 (dd, J = 1.64, 7.96 Hz, 1H), 7.30 (d, J = 8.08 Hz, 1H), 
7.17 (t, J = 7.45 Hz, 4H), 6.72 (q, J = 7.58 Hz, 2H), 6.63 (dd, J = 8.08, 14.65 Hz, 4H), 4.45 (s, 
2H), 4.33 (s, 2H). 13C NMR (100 MHz, CDCl3): δ ppm 157.6, 148.3, 147.5, 136.1, 133.4, 129.2, 
121.6, 118.0, 117.6, 112.9, 48.9, 45.5. HRMS: m/z [M + H]+ calcd for C19H20N3: 290.1652, found: 
290.1643. 
 
2,5-Bis(2-methylanilinomethyl)pyridine (7b). 28% yield as yellow oil. 1H NMR (400 MHz, 
CDCl3): δ ppm 8.61 (d, J = 1.01 Hz, 1H), 7.65 (dd, J = 1.77, 8.08 Hz, 1H), 7.30 (d, J = 7.83 Hz, 
1H), 7.05 - 7.12 (m, 4H), 6.68 (q, J = 7.83 Hz, 2H), 6.57 (d, J = 7.83 Hz, 2H), 4.50 (s, 2H), 4.38 
(s, 2H), 2.23 - 2.28 (m, 9H), 2.16 (s, 8H). 13C NMR (100 MHz, CDCl3): δ ppm 157.6, 148.5, 145.8, 
136.0, 135.4, 130.1, 127.1, 122.3, 121.5, 117.6, 110.0, 48.9, 45.5. HRMS: m/z [M + H]+ calcd for 
C21H24N3: 318.1965, found: 318.1950. 
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2,5-Bis(3-methylanilinomethyl)pyridine (7c). 29% yield as yellow oil. 1H NMR (400 MHz, 
CDCl3): δ ppm 8.57 (s, 1H), 7.63 (dd, J = 1.64, 7.96 Hz, 1H), 7.29 (d, J = 8.08 Hz, 1H), 7.05 (t, J 
= 7.71 Hz, 2H), 6.55 (t, J = 7.96 Hz, 2H), 6.40 - 6.50 (m, 4H), 4.43 (s, 2H), 4.31 (s, 2H), 2.26 (s, 
6H). 13C NMR (100 MHz, CDCl3): δ ppm 157.6, 148.3, 147.6, 139.0, 136.0, 133.4, 129.1, 121.5, 
118.9, 118.6, 113.7, 110.0, 48.9, 45.5, 21.6. HRMS: m/z [M + H]+ calcd for C21H24N3: 318.1965, 
found: 318.1953. 
 
2,5-Bis(4-methylanilinomethyl)pyridine (7d). 23% yield as yellow solid; MP: 89-91°C. 1H 
NMR (400 MHz, CDCl3): δ ppm 8.56 (s, 1H), 7.63 (dd, J = 1.77, 8.08 Hz, 1H), 7.28 (d, J = 8.08 
Hz, 1H), 6.98 (d, J = 8.08 Hz, 4H), 6.56 (dd, J = 8.34, 15.16 Hz, 4H), 4.41 (s, 2H), 4.30 (s, 2H), 
2.23 (s, 6H). 13C NMR (100 MHz, CDCl3): δ ppm 157.9, 148.5, 145.3, 135.7, 133.4, 129.8, 127.2, 
126.8, 121.4, 113.1, 50.0, 45.9, 20.3. HRMS: m/z [M + H]+ calcd for C21H24N3: 318.1965, found: 
318.1953. 
 
2,5-Bis(4-ethylanilinomethyl)pyridine (7e). 37% yield as yellow solid; MP: 69-72°C. 1H NMR 
(400 MHz, CDCl3): δ ppm 8.56 (s, 1H), 7.62 (dd, J = 1.39, 7.96 Hz, 1H), 7.28 (d, J = 8.08 Hz, 
1H), 7.00 (d, J = 8.08 Hz, 4H), 6.57 (dd, J = 8.21, 15.28 Hz, 4H), 4.38 - 4.45 (m, 2H), 4.28 (s, 2H), 
2.53 (q, J = 7.58 Hz, 4H), 1.17 (t, J = 7.58 Hz, 6H). 13C NMR (100 MHz, CDCl3): δ ppm 157.8, 
148.4, 145.5, 135.9, 133.8, 128.6, 121.4, 113.0, 49.3, 45.8, 27.9, 15.9. HRMS: m/z [M + H]+ calcd 
for C23H28N3: 346.2278, found: 346.2261. 
 
2,5-Bis(2-methoxyanilinomethyl)pyridine (7f). 15% yield as yellow oil. 1H NMR (400 MHz, 
CDCl3): δ ppm 8.58 (d, J = 1.77 Hz, 1H), 7.66 - 7.70 (m, 1H), 7.34 (d, J = 8.08 Hz, 1H), 7.09 (d, 
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J = 5.05 Hz, 1H), 6.68 (s, 1H), 6.56 (s, 1H), 4.73 (s, 2H), 4.51 (s, 2H), 4.12 (q, J = 7.24 Hz, 8H). 
13C NMR (100 MHz, CDCl3): δ ppm 170.86, 147.8, 145.5, 135.3, 129.8, 126.8, 122.0, 121.1, 
116.9, 109.8, 62.4, 48.8. HRMS: m/z [M + H]+ calcd for C21H24N3O2: 350.1863, found: 350.1869. 
 
2,5-Bis(3-methoxyanilinomethyl)pyridine (7g). 41% yield as purple oil. 1H NMR (400 MHz, 
CDCl3): δ ppm 8.56 (s, 1H), 7.63 (dd, J = 1.77, 7.83 Hz, 1H), 7.28 (d, J = 8.08 Hz, 1H), 7.07 (t, J 
= 8.08 Hz, 2H), 6.14 - 6.33 (m, 6H), 4.42 (s, 2H), 4.31 (s, 2H), 3.74 (S, 6H). 13C NMR (100 MHz, 
CDCl3): δ ppm 160.7, 157.4, 149.0, 148.4, 135.9, 133.2, 130.1, 121.5, 106.0, 103.0, 99.0, 55.0, 
48.9, 45.5. HRMS: m/z [M + H]+ calcd for C21H24N3O2: 350.1863, found: 350.1850. 
 
2,5-Bis(4-methoxyanilinomethyl)pyridine (7h). 31% yield as yellow oil. 1H NMR (400 MHz, 
CDCl3): δ ppm 8.58 (s, 1H), 7.65 (dd, J = 1.64, 7.96 Hz, 1H), 7.39 (d, J = 8.84 Hz, 2H), 7.30 (d, J 
= 8.08 Hz, 1H), 6.86 (d, J = 9.09 Hz, 2H), 6.78 (d, J = 8.84 Hz, 4H), 6.61 (dd, J = 8.84, 14.15 Hz, 
4H), 4.40 (s, 2H), 4.30 (s, 2H), 3.74 (s, 6H). 13C NMR (100 MHz, CDCl3): δ ppm 157.9, 156.4, 
146.6, 136.0, 133.5, 121.9, 114.9, 114.3, 55.7, 50.0, 46.5. HRMS: m/z [M + H]+ calcd for 
C21H24N3O2: 350.1863, found: 350.1851. 
 
2,5-Bis(2-fluoroanilinomethyl)pyridine (7i). 6% yield as yellow oil. 1H NMR (400 MHz, 
CDCl3): δ ppm 8.61 (d, J = 1.52 Hz, 1H), 7.65 - 7.70 (m, 1H), 7.33 (d, J = 8.08 Hz, 1H), 6.92 - 
7.03 (m, 3H), 6.59 - 6.70 (m, 4H), 4.50 (s, 2H), 4.40 (s, 2H). 13C NMR (100 MHz, CDCl3): δ ppm 
157.5, 148.6, 135.9, 133.0, 124.6, 121.4, 117.0, 114.6, 114.5, 112.3, 48.7, 45.1. HRMS: m/z [M + 
H]+ calcd for C19H18N3F2: 326.1469, found: 326.1482. 
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2,5-Bis(3-fluoroanilinomethyl)pyridine (7j). 27% yield as yellow oil. 1H NMR (400 MHz, 
CDCl3): δ ppm 8.55 (s, 1H), 7.62 (d, J = 7.83 Hz, 1H), 7.23 - 7.30 (m, 1H), 7.08 (q, J = 7.75 Hz, 
2H), 6.25 - 6.43 (m, 6H), 4.40 (s, 2H), 4.31 (s, 2H). 13C NMR (100 MHz, CDCl3): δ ppm 165.2, 
162.8, 157.0, 149.6, 148.3, 135.9, 132.9, 130.2, 121.6, 108.9, 104.5, 99.8, 48.7, 45.3. HRMS: m/z 
[M + H]+ calcd for C19H18N3F2: 326.1469, found: 326.1459. 
 
2,5-Bis(4-fluoroanilinomethyl)pyridine (7k). 12% yield as orange oil. 1H NMR (400 MHz, 
CDCl3): δ ppm 8.57 (s, 1H), 7.65 (d, J = 8.08 Hz, 1H), 7.29 (d, J = 8.08 Hz, 1H), 6.88 (t, J = 8.46 
Hz, 4H), 6.50 - 6.62 (m, 4H), 4.40 (s, 2H), 4.30 (s, 2H). 13C NMR (100 MHz, CDCl3): δ ppm 
157.4, 148.5, 145.9, 135.9, 138.2, 121.5, 115.8, 113.8, 49.6, 46.1. HRMS: m/z [M + H]+ calcd for 
C19H18N3F2: 326.1469, found: 326.1474. 
 
2,5-Bis(4-chloroanilinomethyl)pyridine (7l). 30% yield as yellow solid; MP: 113-114°C. 1H 
NMR (400 MHz, CDCl3): δ ppm 8.52 - 8.58 (m, 1H), 7.62 (dd, J = 2.02, 8.08 Hz, 1H), 7.28 (s, 
1H), 7.06 - 7.15 (m, 4H), 6.49 - 6.60 (m, 4H), 4.40 (s, 2H), 4.31 (s, 2H). 13C NMR (100 MHz, 
CDCl3): δ ppm 157.10, 148.41, 146.3, 135.8, 133.0, 129.1, 122.6, 121.5, 114.0, 48.9, 45.5. HRMS: 
m/z [M + H]+ calcd for C19H18N3Cl2: 358.0872, found: 358.0855. 
 
2,5-Bis(4-bromoanilinomethyl)pyridine (7m). 30% yield as yellow solid; MP: 144-146°C. 1H 
NMR (400 MHz, CDCl3): δ ppm 8.53 - 8.58 (m, 1H), 7.62 (dd, J = 2.15, 7.96 Hz, 1H), 7.20 - 7.29 
(m, 5H), 6.45 - 6.56 (m, 4H), 4.39 (s, 2H), 4.31 (s, 2H). 13C NMR (100 MHz, CDCl3): δ ppm 
157.0, 148.4, 146.7, 135.8, 132.9, 131.9, 121.5, 114.6, 109.6, 109.2, 48.8, 45.4. HRMS: m/z [M + 
H]+ calcd for C19H18N3Br2: 445.9862, found: 445.9858. 
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2,5-Bis(2-nitroanilinomethyl)pyridine (7n). 7% yield as yellow oil. 1H NMR (400 MHz, 
CDCl3): δ ppm 8.80 (s, 2H), 8.14 (dd, J = 1.39, 8.72 Hz, 1H), 7.98 - 8.03 (m, 2H), 7.91 - 7.96 (m, 
2H), 7.37 (d, J = 8.59 Hz, 1H), 6.83 (dd, J = 1.01, 8.34 Hz, 1H), 6.73 (dd, J = 1.26, 7.07, 8.59 Hz, 
1H), 6.04 - 6.13 (m, 1H), 4.84 - 4.92 (m, 4H). 13C NMR (100 MHz, CDCl3): δ ppm 152.2, 148.6, 
140.8, 136.2, 135.3, 132.3, 126.2, 122.8, 121.6, 118.7, 117.0, 62.3, 56.0. HRMS: m/z [M + H]+ 
calcd for C19H18N5O4: 380.1359, found: 380.1349. 
 
2,5-Bis(3-nitroanilinomethyl)pyridine (7o). 7% yield as yellow oil. 1H NMR (400 MHz, CDCl3): 
δ ppm 8.56 (d, J = 1.01 Hz, 1H), 7.72 (dd, J = 2.15, 7.96 Hz, 1H), 7.51 - 7.59 (m, 2H), 7.41 - 7.48 
(m, 2H), 7.26 - 7.35 (m, 4H), 6.88 - 6.98 (m, 2H), 4.75 (s, 2H), 4.49 (d, J = 4.80 Hz, 2H). 13C NMR 
(100 MHz, CDCl3): δ ppm 156.1, 148.0, 135.8, 129.7, 121.6, 119.1, 112.2, 106.5, 62.5, 48.4. 
HRMS: m/z [M + H]+ calcd for C19H18N5O4: 380.1353, found: 380.1345. 
 
2,5-Bis(4-nitroanilinomethyl)pyridine (7p). 7% yield as yellow oil. 1H NMR (400 MHz, 
CDCl3): δ ppm 8.56 (s, 1H), 8.02 - 8.14 (m, 3H), 7.74 (d, J = 7.83 Hz, 1H), 7.24 - 7.35 (m, 2H), 
6.56 - 6.68 (m, 3H), 5.93 (br. s., 1H), 4.76 (s, 2H), 4.52 (d, J = 5.05 Hz, 2H). 13C NMR (100 MHz, 
CDCl3): δ ppm 152.8, 147.9, 135.9, 126.4, 121.5, 111.5, 62.4, 47.7. HRMS: m/z [M + H]+ calcd 
for C19H18N5O4: 380.1359, found: 380.1375. 
 
4.2 Biology 
Our collaborators from Dr. Hyunsuk Shim’s lab at Emory University performed all the biological 
assays. 
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4.2.1 Binding Affinity Assay Procedure 
A competitive assay where MDA-MB-231 breast cancer cells are incubated in an 8-well slide 
chamber with the analogues at 1, 10, 100, and 1000 nM concentration for two days in 300 µL of 
medium. The cells were fixed with 4% paraformaldehyde and rehydrated with phosphate-buffer 
saline (PBS) solution. The slides were incubated with 0.05 µg/mL biotinylated TN14003 for thirty 
minutes at room temperature, washed three times with PBS solution, and incubated with 
streptavidin-conjugate rhodamine (1:150 dilution; Jackson ImmunoResearch Laboratories, West 
Grove, PA) for thirty minutes at room temperature. They were then washed with PBS solution, 
mounted in an antifade mounting solution (Molecular Probes, Eugene, OR), and analyzed using 
Nikon Eclipse E800 microscope. 57, 58 
 
4.2.2 Matrigel Invasion Assay Procedure 
Matrigel invasion chambers (Coring Biocoat; Bedford, MA) were used to conduct this assay. In 
the top chamber, MDA-MB-231 cells were placed with 100 nM of the analogue or AMD3100 (for 
control). In the bottom chamber, 200 ng/mL solution of CXCR4 (R&D Systems, Minneapolis, 
MN) is added. The apparatus is incubated for 22 hours in a humidified incubator. After incubation, 
the excess cells in the top chamber are removed using a cotton swab and the cells in the bottom 
chamber are stained with hematoxylin and eosin (H&E) and fixed with methanol. The rate of 
invasion is calculated using the number of invaded cells.57, 58 
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4.2.3 Carrageenan Paw Edema Test Procedure 
Female mice (C57Bl/6J; Jackson Laboratories) were used for this test. In a hind paw of the mice, 
inflammation was triggered by injecting λ-carrageenan (50 µL in 1% w/v in saline) while the other 
was used as a non-inflammation control. The testing analogues were prepared in 10% DMSO and 
90% of 45% (2-hydroxypropyl)-β-cyclodextrin (CD) in PBS. TN14003 doses were set at 300 
µg/kg, where the analogues were set at 10 mg/kg. The TN14003 dose was set at a lower 
concentration because the concentration was found to give maximum efficacy at minimum 
concentration in an animal model for breast cancer metastasis. The mice were given the dose thirty 
minutes after the carrageenan injection and once a day after the initial dose. The mice were 
scarified after 74 hours after induction of inflammation and two hours after the last dosage of drug. 
The paws were measured for thickness from front to back using calipers and photographed before 
sacrificing. The measurement from the untreated paw was subtracted from the volume of the 
carrageenan injected paw to attain the edema volume. The inflammation suppression percentage 
was calculated by comparing the control group and the drug treated group. Each analogue was 
tested in quintuplicate using the procedure above.  
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6 APPENDICES 
NMR Spectra 
1H NMR Spectrum for Compound 3a  
 
N
H
N
N
H
 
 
 52 
13C NMR Spectrum for Compound 3a 
  
N
H
N
N
H
 
 
 53 
1H NMR Spectrum for Compound 3b  
  
N
H
N
N
H
 
 
 54 
13C NMR Spectrum for Compound 3b 
  
N
H
N
N
H
 
 
 55 
1H NMR Spectrum for Compound 3c 
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1H NMR Spectrum for Compound 3d 
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1H NMR Spectrum for Compound 3e 
 
  
N
H
N
N
H
 
 
 60 
13C NMR Spectrum for Compound 3e 
 
  
N
H
N
N
H
 
 
 61 
1H NMR Spectrum for Compound 3f 
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MS Spectra 
Mass Spectra for Compound 3a  
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Mass Spectra for Compound 3b  
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Mass Spectra for Compound 3c 
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Mass Spectra for Compound 3d 
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Mass Spectra for Compound 3e 
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Mass Spectra for Compound 3f 
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T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 3g 
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T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 3h 
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Mass Spectra for Compound 3i 
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T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 3j  
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T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 3k 
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T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 3l 
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SV_43_ESIPOS_MOORING_110217 #127-133 RT: 1.78-1.87 AV: 7 NL: 4.00E8
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 3m  
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SV_42_ESIPOS_MOORING_110217 #123-131 RT: 1.74-1.85 AV: 9 NL: 1.09E8
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 3n 
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SV_51_ESIPOS_MOORING_122217_171222111336 #143 RT: 2.02 AV: 1 NL: 1.09E6
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 3o 
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SV_36_ESIPOS_MOORING_110217 #139-147 RT: 1.96-2.07 AV: 9 NL: 2.37E8
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 3p 
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SV_35_ESIPOS_MOORING_110217 #137-146 RT: 1.94-2.06 AV: 10 NL: 1.04E8
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 7a  
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SV_56_ESIPOS_MOORING_020818 #120-128 RT: 1.70-1.81 AV: 9 NL: 2.30E8
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 7b  
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T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 7c 
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SV_60_ESIPOS_MOORING_020818 #145-147 RT: 2.04-2.07 AV: 3 NL: 1.48E8
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 7d 
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SV_59_ESIPOS_MOORING_020818 #123-126 RT: 1.74-1.78 AV: 4 NL: 2.22E8
T: FTMS + p ESI Full ms [50.00-1000.00]
304 306 308 310 312 314 316 318 320 322 324 326 328 330 332 334 336
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
el
at
iv
e 
A
bu
nd
an
ce
318.1951
z=1
319.1981
z=1
 
 
 137 
Mass Spectra for Compound 7e 
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SV_62_ESIPOS_MOORING_021418 #104-107 RT: 1.46-1.50 AV: 4 NL: 2.24E8
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 7f  
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Mass Spectra for Compound 7g 
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SV_57_ESIPOS_MOORING_020818 #126-131 RT: 1.78-1.85 AV: 6 NL: 2.57E8
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 7h 
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SV_55_ESIPOS_MOORING_020818 #148-157 RT: 2.08-2.20 AV: 10 NL: 1.10E8
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 7i 
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Mass Spectra for Compound 7j  
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Mass Spectra for Compound 7k 
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Mass Spectra for Compound 7l 
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SV_70_ESIPOS_MOORING_022218 #192 RT: 2.68 AV: 1 NL: 6.04E7
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 7m  
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SV_69_ESIPOS_MOORING_022218 #102 RT: 1.44 AV: 1 NL: 5.41E5
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 7n  
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Mass Spectra for Compound 7o 
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SV_67_ESIPOS_MOORING_022218 #155 RT: 2.18 AV: 1 NL: 4.17E5
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for Compound 7p 
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